OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Science is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Emerging role of carbonic anhydrase inhibitors	127
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer	125
The complex role of adipokines in obesity, inflammation, and autoimmunity	121
Pathogenesis of pneumonia and acute lung injury	109
The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease	100
Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways	100
Gut microbiota-derived butyrate regulates gut mucus barrier repair by activating the macrophage/WNT/ERK signaling pathway	91
M1/M2 macrophages and their overlaps – myth or reality?	80
Mechanisms of podocyte injury and implications for diabetic nephropathy	72
ACE2 and gut amino acid transport	70
Negative regulators of TGF-β1 signaling in renal fibrosis; pathological mechanisms and novel therapeutic opportunities	63
Sepsis plasma-derived exosomal miR-1-3p induces endothelial cell dysfunction by targeting SERP1	61
The immune niche of the liver	57
Cholesterol metabolism: a new molecular switch to control inflammation	53
Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression	52
Buformin alleviates sepsis-induced acute lung injury via inhibiting NLRP3-mediated pyroptosis through an AMPK-dependent pathway	52
Cardiotoxic effects of angiogenesis inhibitors	50
ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV	50
Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19	48
Inflammation: a putative link between phosphate metabolism and cardiovascular disease	45
ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19	44
The GCN5: its biological functions and therapeutic potentials	43
Gut microbiome dysbiosis alleviates the progression of osteoarthritis in mice	40
Klotho and calciprotein particles as therapeutic targets against accelerated ageing	40
Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice	40

Interplay between extracellular matrix components and cellular and molecular mechanisms in kidney fibrosis	40
Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists	38
ACE2: from protection of liver disease to propagation of COVID-19	38
Epigenetic processes during preeclampsia and effects on fetal development and chronic health	38
ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease	37
Brahma-related gene-1 promotes tubular senescence and renal fibrosis through Wnt/β-catenin/autophagy axis	37
ACE2 in the renin–angiotensin system	37
Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer’s disease	36
Host cell glutamine metabolism as a potential antiviral target	36
Role of ACE2 in pregnancy and potential implications for COVID-19 susceptibility	35